Coya Therapeutics Inc. (COYA): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
COYA Stock Price Chart Interactive Chart >
COYA Price/Volume Stats
| Current price | $4.04 | 52-week high | $5.67 |
| Prev. close | $4.24 | 52-week low | $3.68 |
| Day low | $3.92 | Volume | 46,000 |
| Day high | $4.56 | Avg. volume | 20,164 |
| 50-day MA | $4.42 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 39.10M |
Latest COYA News From Around the Web
Below are the latest news stories about COYA THERAPEUTICS INC that investors may wish to consider to help them evaluate COYA as an investment opportunity.
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ETHOUSTON, March 09, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), on Tuesday, March 21, 2023 at 8:00am ET. |
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?By David Willey, Benzinga |
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in DallasCoya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary in... |
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.HOUSTON, February 27, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, |
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases TreatmentsBy Ernest Dela Aglanu, Benzinga |
COYA Price Returns
| 1-mo | -3.35% |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -14.73% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...